Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte Announces New Prospective Data Demonstrating That Treatment Informed by DetermaRx™ Significantly Improves Lung Cancer Patient Survival

Data to be Presented by Dr. Gavitt Woodard of Yale University at the IASLC 2020 North America Conference on Lung Cancer Results and Clinical Utility to be Discussed During KOL Webinar on October 22nd...
October 08, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte and Fondazione Michelangelo, a Leading Non-Profit Cancer Research Foundation, Announce Immune Therapy Biomarker Collaboration

Investigator-sponsored trial to evaluate DetermaIO™ as a biomarker of neoadjuvant checkpoint inhibitor response in triple-negative breast cancer (TNBC) Collaboration to generate near-term...
October 01, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte Agrees to Enter Licensing and Collaboration Agreement with Chronix Biomedical

Chronix’s blood-based test monitors the effectiveness of immunotherapy drugs in clinical trials, and potentially in patients receiving immunotherapy treatment Further extends Oncocyte’s product...
September 14, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte to Participate at the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference

IRVINE, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
September 09, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte Receives Final Pricing Decision for DetermaRx™ Molecular Test for Lung Cancer from Centers for Medicare and Medicaid Services

Pricing in line with comparable high-value molecular tests for oncology indications Consistent growth in testing volumes now provides immediate and consistent revenue for Oncocyte DetermaRx is...
September 03, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte and the Guardian Research Network® Announce Strategic Alliance

Collaboration establishes an integrated platform for precision medicine clinical trials, combining Oncocyte’s proprietary molecular tests and fully certified pharma services lab with GRN’s nationwide...
August 27, 2020 08:00 ET | Source: OncoCyte Corporation

Oncocyte Announces Addition of Experienced Healthcare Executive, Jennifer Carter, MD, MPH, MBA to Board of Directors

IRVINE, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
August 13, 2020 16:05 ET | Source: OncoCyte Corporation

Oncocyte to Participate at Needham Virtual Cancer Diagnostics Conference

IRVINE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
August 11, 2020 08:00 ET | Source: OncoCyte Corporation

Oncocyte to Hold KOL Webinar Highlighting Clinical Data on Its DetermaIO™ Test for Immunotherapy Response Prediction

Event to feature Dr. Naoto Ueno, study investigator and medical oncologist at the University of Texas MD Anderson Cancer Center DetermaIO™, a novel and proprietary test, has been found to...
July 29, 2020 16:05 ET | Source: OncoCyte Corporation

Oncocyte Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Secured National Medicare Reimbursement for DetermaRx™ Starting August 2020 with Final Medicare LCD from Palmetto GBA and Noridian Healthcare Solutions International Distribution...